Elevation Oncology Inc
NASDAQ:ELEV
Intrinsic Value
Elevation Oncology, Inc. operates as a precision oncology company. [ Read More ]
The intrinsic value of one ELEV stock under the Base Case scenario is 1.09 USD. Compared to the current market price of 4.07 USD, Elevation Oncology Inc is Overvalued by 73%.
Valuation Backtest
Elevation Oncology Inc
Run backtest to discover the historical profit from buying and selling ELEV stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Elevation Oncology Inc
Current Assets | 88m |
Cash & Short-Term Investments | 83.1m |
Other Current Assets | 4.9m |
Non-Current Assets | 1.1m |
PP&E | 59k |
Other Non-Current Assets | 1.1m |
Current Liabilities | 4.1m |
Accounts Payable | 507k |
Accrued Liabilities | 3.6m |
Non-Current Liabilities | 30.1m |
Long-Term Debt | 30.1m |
Earnings Waterfall
Elevation Oncology Inc
Revenue
|
0
USD
|
Operating Expenses
|
-40.3m
USD
|
Operating Income
|
-40.3m
USD
|
Other Expenses
|
-5.4m
USD
|
Net Income
|
-45.7m
USD
|
Free Cash Flow Analysis
Elevation Oncology Inc
What is Free Cash Flow?
ELEV Profitability Score
Profitability Due Diligence
Elevation Oncology Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Elevation Oncology Inc's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
ELEV Solvency Score
Solvency Due Diligence
Elevation Oncology Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Score
Elevation Oncology Inc's solvency score is 47/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ELEV Price Targets Summary
Elevation Oncology Inc
According to Wall Street analysts, the average 1-year price target for ELEV is 7.91 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.
Ownership
ELEV Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ELEV Price
Elevation Oncology Inc
Average Annual Return | -66.03% |
Standard Deviation of Annual Returns | 25.77% |
Max Drawdown | -98% |
Market Capitalization | 198m USD |
Shares Outstanding | 48 651 100 |
Percentage of Shares Shorted | 11.44% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Elevation Oncology, Inc. operates as a precision oncology company. The company is headquartered in New York City, New York and currently employs 35 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development of targeted therapeutics for the treatment of cancer in genomically-defined patient populations. The company focuses on identifying oncogenic drivers with other driver alterations and in the conduct of clinical trials. Its lead drug development candidate, seribantumab, is an Anti-HER3 monoclonal antibody and potential targeted therapy for solid tumors driven by neuregulin-1 (NRG1) fusions, which are genomic alterations that are identified as oncogenic driver alterations. Its NRG1 is the primary activating ligand of HER3. The firm's clinical trial, CRESTONE, is a Phase II study of seribantumab in cancer patients with a solid tumor of any origin that expresses a genomic change called an NRG1 fusion.
Contact
IPO
Employees
Officers
The intrinsic value of one ELEV stock under the Base Case scenario is 1.09 USD.
Compared to the current market price of 4.07 USD, Elevation Oncology Inc is Overvalued by 73%.